Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

September 14, 2021; 97 (11) Viewpoint

Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease

Stephen Salloway, Jeffrey Cummings
First published July 7, 2021, DOI: https://doi.org/10.1212/WNL.0000000000012451
Stephen Salloway
From Butler Hospital and Warren Alpert Medical School of Brown University (S.S.), Providence, RI; and Chambers-Grundy Center for Transformative Neuroscience (J.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Cummings
From Butler Hospital and Warren Alpert Medical School of Brown University (S.S.), Providence, RI; and Chambers-Grundy Center for Transformative Neuroscience (J.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
Stephen Salloway, Jeffrey Cummings
Neurology Sep 2021, 97 (11) 543-544; DOI: 10.1212/WNL.0000000000012451

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1915

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Aducanumab (Aduhelm) was recently approved by the US Food and Drug Administration (FDA) for the treatment of Alzheimer disease (AD). The approval of aducanumab is controversial. We address why we support this decision and welcome the availability of aducanumab as an important therapy for patients with early AD.

Building on a phase 1B study that informed dose decisions and demonstrated amyloid lowering by aducanumab, Biogen launched 2 phase 3 trials: EMERGE and ENGAGE.1 These were identically designed global trials with 1,600 amyloid-positive participants with early AD in each trial. At trial initiation, participants were randomized to high dose, low dose, or placebo. A dose increase from 6 mg/kg to 10 mg/kg was made for APOE4 gene carriers midway through the trial; EMERGE participants had higher doses for longer periods as the EMERGE trial began later than the ENGAGE trial and patients had more time on the 10 mg/kg dose. An interim efficacy analysis showed no foreseeable drug–placebo difference, and both trials were stopped. Blinded data continued to accrue and the final data set at week 78 demonstrated that EMERGE met its primary outcome with a 22% drug–placebo difference in slowing on the Clinical Dementia Rating sum of boxes (CDR-SB) in the high-dose group (p = 0.01). Secondary outcomes on standard clinical trial instruments showed significant drug–placebo differences in favor of aducanumab with greater decline in the placebo group than in the aducanumab group in the course of the trial: the AD Assessment Scale–cognitive subscale showed a 27% drug–placebo difference (p = 0.009), the AD Cooperative Study activities of daily living mild cognitive impairment scale demonstrated a 40% drug–placebo difference (p = 0.0006), and the Mini-Mental State Examination exhibited an 18% difference (p = 0.04). Functional measures are used to determine the clinical meaningfulness of a treatment response2; a 40% reduction in functional decline is statistically significant and clinically important. Amyloid lowering was robust and statistically significant in both dose groups. CSF biomarker analyses revealed significant dose-related reductions in hyperphosphorylated tau in the active treatment groups. Pooled EMERGE and ENGAGE data for tau PET showed increases in the placebo group and less increase or decreases in the high-dose group in several cortical regions. The ENGAGE trial showed no drug–placebo difference for the primary and secondary clinical outcomes in the final data set. There was significant amyloid lowering in both dose arms. Of ENGAGE participants who had completed 14 months of treatment at the 10 mg/kg dose (the dose recommended in the package insert), there was a 27% slowing on the CDR-SB comparable to the slowing observed in EMERGE. The principal adverse events occurring in both trials were amyloid-related imaging abnormalities occurring in 34% of those in the EMERGE high-dose group and 35.5% in the ENGAGE high-dose group and leading to 6.6% and 7.3% discontinuations in EMERGE and ENGAGE, respectively.

The FDA approved aducanumab using the accelerated approval pathway that allows marketing of a drug based on a biomarker considered reasonably likely to predict clinical benefit. Accelerated approval is accompanied by a requirement to generate additional efficacy and safety data in a postmarketing study. The biomarker considered likely to predict clinical benefit was plaque lowering demonstrated by amyloid PET.

The body of evidence supporting use of aducanumab in patients with early AD includes consistent amyloid reduction on PET imaging, slowing of decline on primary and secondary outcome measures in EMERGE, encouraging effects on biomarkers consistent with effect on biological processes linked to disease progression, and preliminary observations of slowing of cognitive decline in other trials of plaque-lowering antibodies (e.g., donanemab3). The absence of disease-modifying therapies for AD supports making the therapy available on the basis of these data. Further study is required to confirm clinical benefits and to identify individuals most likely to respond.

Implementation of aducanumab will make new demands on the health care system, including clinician vigilance for patients with early AD; availability of amyloid PET, lumbar puncture, and MRI resources; and access to infusion centers. We recommend that the patients treated with aducanumab have features similar to those included in the EMERGE/ENGAGE trials: early symptomatic AD with evidence of brain amyloid. Progress in the development of a blood test for AD diagnosis would accelerate the integration of aducanumab into the diagnostic/therapeutic workflow. Successful implementation of aducanumab will require collaboration among primary care clinicians and specialists and a commitment to equity of access.

Aducanumab opens a new era in AD research and care and provides a foundation for development of progressively better therapies.

Study Funding

The authors report no targeted funding.

Disclosure

S. Salloway was a site PI and co-chair of the investigator steering committee for the ENGAGE trial and receives research support and consultancy fees from Biogen, Eisai, Lilly, Avid, Genentech, and Roche. J. Cummings has provided consultation to Biogen, Eisai, Acadia, Alkahest, AriBio, Avanir, Axsome, Behren Therapeutics, Cassava, Cerecin, Cerevel, Cortexyme, EIP Pharma, GemVax, Genentech, Green Valley, Grifols, Janssen, Jazz, Karuna, LSP, Merck, Novo Nordisk, Otsuka, ReMYND, Resverlogix, Roche, Signant Health, Sunovion, Suven, United Neuroscience, and Unlearn AI pharmaceutical and assessment companies; owns the copyright of the Neuropsychiatric Inventory; and has the following research support: NIGMS P20GM109025, NINDS U01NS093334, NIA R01AG053798, NIA P20AG068053, NIA R35AG71476. Go to Neurology.org/N for full disclosures.

Appendix Authors

Table
Table

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Editorial, page 517

  • See page 545

  • Received June 15, 2021.
  • Accepted in final form June 23, 2021.
  • © 2021 American Academy of Neurology

References

  1. 1.↵
    US Food and Drug Administration. Combined FDA and applicant PCNS Drugs Advisory Committee briefing document. Accessed July 4, 2021. https://www.fda.gov/media/143502/download.
  2. 2.↵
    1. Leber P
    . Guidelines for the clinical evaluation of antidementia drugs. Food and Drug Administration; 1990.
  3. 3.↵
    1. Mintun MA,
    2. Lo AC,
    3. Duggan Evans C, et al
    . Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384(18):1691-1704.
    OpenUrlPubMed

Letters: Rapid online correspondence

  • Reader Response: Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
    • Eugene Scharf, Neurologist, Mayo Clinic
    Submitted September 14, 2021
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Study Funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • Clinical Efficacy, Drug Safety, and Surrogate EndpointsHas Aducanumab Met All of Its Expectations?
  • Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
    Douglas Galasko, Joanne Bell, Jessica Y. Mancuso et al.
    Neurology, April 02, 2014
  • Editorial
    Clinical Efficacy, Drug Safety, and Surrogate Endpoints
    Has Aducanumab Met All of Its Expectations?
    Linda A. Hershey, Rawan Tarawneh et al.
    Neurology, July 07, 2021
  • Views & Reviews
    Disease-modifying therapies for Alzheimer disease
    Challenges to early intervention
    Jeffrey L. Cummings, Rachelle Doody, Christopher Clark et al.
    Neurology, October 15, 2007
  • Article
    ABBY
    A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease
    Jeffrey L. Cummings, Sharon Cohen, Christopher H. van Dyck et al.
    Neurology, April 25, 2018
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise